title: [New aspects of the determination of blood methotrexate levels in leukemic children].
abstract: Serum and CSF concentrations after medium dosage of methotrexate (MTX; 500 mg/m2 - 1,000 mg/m2) have been determined by an enzymatic assay during 142 infusions in children with ALL. If the dose of MTX was 500 mg/m2 MTX concentrations in CSF were under 10(-6) M/l in 40% of the treatments but only in 22%, when the dose was increased to 1,000 mg/m2. The systemic clearance of MTX was found to be increased significantly by the 2nd MTX treatment in children who relapsed thereafter. Such a phenomenon was not observed in children who continued in remission. The relapse free survival of children, whose MTX-clearance remained constant by the 2nd MTX treatment was significantly longer. No serious MTX toxicity has been observed in our patients.
authors.forename: D
authors.initials: D
authors.lastname: Schuler
authors.forename: J
authors.initials: J
authors.lastname: Borsi
authors.forename: R
authors.initials: R
authors.lastname: Koós
authors.forename: T
authors.initials: T
authors.lastname: Révész
authors.forename: G
authors.initials: G
authors.lastname: Kardos
authors.forename: P
authors.initials: P
authors.lastname: Somló
mesh_terms: D001812:Blood-Brain Barrier; D002648:Child; D006801:Humans; D007262:Infusions, Intravenous; D007945:Leukemia, Lymphoid / Q000097:blood / Q000188:drug therapy*; D008657:Metabolic Clearance Rate; D008727:Methotrexate / Q000097:blood* / Q000627:therapeutic use; D011379:Prognosis
chemical_list: D008727:Methotrexate
vernacular_title: Neue Aspekte der Methotrexat-Blutspiegelbestimmungen bei leukämischen Kindern.